Loading
AI
Avantor, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 May 2026.
Avantor, Inc.: what insiders have been doing
This page follows insider dealings at Avantor, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 14 insiders published 31 filings.
Only purchases show up on the open market, 7 purchases in all worth €7.4M, filed by 5 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Mehra Sanjeev K filed the largest purchase, €3.3M, on 9 December 2025. The buyers include 4 senior executives and 1 chief executive.
Across the 5,811 companies tracked on its exchange, the median is 19 filings; at 31 filings, this issuer sits above that mark. Since 2021, the database holds 21 purchases and 37 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 6.55 bn USD and net income of -530.2 m USD.
In the case of 4 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 5 May 2026, 166 days ago. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
293
Thresholds
n/a
Buy Volume
€11M
21 ops. · all time
Sell Volume
€109M
37 ops. · all time
Who traded when
BuySaleGregory L. Summe7 buys
Sanjeev K. Mehra2 buys
Steven W. Eck2 sales
Emmanuel Ligner1 buy
Gregory T. Lucier1 buy
James Bramwell1 sale
+4 other insiders
Since the insiders bought
- +62.3%Entry US$8.43 · Close at T+90 US$13.68
- +22.2%Entry US$7.90 · Close at T+90 US$9.65
- -10.6%Entry US$9.11 · Close at T+90 US$8.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Avantor, Inc. Hold (neutral), based on 14 analysts. Average price target: US$15.46.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,162 of 24,148 companies
34.5
score / 100
Value42
Quality27
FCF yld4.5%
Earn yld-4.9%
EV/EBITDA·
ROE-9.7%
Gross mgn33%
Net mgn-8.1%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.09
Analyst consensus
14 analystsHold
US$13.00Target US$15.46(-4%)US$19.00
Income statement
RevenueUS$6.6B
Gross profitUS$2.1B33% margin
EBITDAUS$138.7M2% margin
Net income-US$530.2M-8.8% margin
Valuation
PER (forward)18.3x
P/Book1.9x
Beta0.94
Balance sheet & cash
Market capUS$10.9B
Total debtUS$3.9B
Free Cash FlowUS$495M
Debt / Equity66%
Profitability & ownership
ROE-9.7%
ROA2.7%
% insiders1.5%
% institutions105.7%
Last declaration on 23 September 2026
Declarations293 total
49,688 shares0Common StockSEC:0001628280-26-063227:0
29,803 shares@ US$13.330.0038% mcap28.6% of flowCommon StockSEC:0001628280-26-058303:0
181 shares@ US$13.660.0000% mcap4.5% of flowCommon StockSEC:0001628280-26-057645:0
1,385 shares@ US$13.780.0002% mcap1.4% of flowCommon StockSEC:0001628280-26-052722:0
1,201 shares@ US$11.440.0001% mcap9.2% of flowCommon StockSEC:0001628280-26-049853:0
3,010 sharesCommon StockSEC:0001628280-26-044719:0
25,000 shares@ US$8.140.0022% mcap100.0% of flowCommon StockSEC:0001628280-26-030826:0
Canonical exit: 30 Jul 2026 (T+90)
146,566 shares0Common StockSEC:0001628280-26-030825:0
31,645 shares0Common StockSEC:0001628280-26-023934:0
125,000 shares@ US$8.0120.5% of flowCommon StockSEC:0001628280-26-016904:0
Canonical exit: 8 Jun 2026 (T+90)
2,376 shares@ US$8.8913.6% of flowCommon StockSEC:0001628280-26-011812:0
1,324 shares@ US$8.8920.9% of flowCommon StockSEC:0001628280-26-011811:0
2,805 shares@ US$8.89100.0% of flowCommon StockSEC:0001628280-26-011810:0
3,029 shares@ US$8.8934.1% of flowCommon StockSEC:0001628280-26-011809:0
2,017 shares@ US$8.891.3% of flowCommon StockSEC:0001628280-26-011808:0
161,237 shares0Common StockSEC:0001628280-26-010828:0
80,618 shares0Common StockSEC:0001628280-26-010827:0
50,000 shares@ US$9.16100.0% of flowCommon StockSEC:0001628280-26-010832:0
Canonical exit: 20 May 2026 (T+90)
48,859 shares0Common StockSEC:0001628280-26-010830:0
483,713 shares0Common StockSEC:0001628280-26-010829:0
80,618 shares0Common StockSEC:0001628280-26-010833:0
235,993 shares0Common StockSEC:0001628280-26-010831:0
134,364 shares0Common StockSEC:0001628280-26-010826:0
161,237 shares0Common StockSEC:0001628280-26-010825:0
100,000 shares@ US$9.4020.1% of flowCommon StockSEC:0001628280-26-007802:0
Canonical exit: 13 May 2026 (T+90)
25 of 293 declarations
About Avantor, Inc.
Avantor, Inc. (NYSE: AVTR) is a U.S.-based global provider of mission-critical products and services to the life sciences and advanced technology industries. The company is headquartered in Radnor, Pennsylvania, in the United States, and its heritage dates back to 1904 through the founding of J.T. Baker Chemical Company. That long operating history matters because Avantor is not a drug developer; it is an enabling platform that supplies the tools, materials and workflow support used across research, development and biomanufacturing. For investors, that makes Avantor a classic “picks-and-shovels” name tied to the broader innovation economy in healthcare and industrial science.
Avantor’s business model is organized around two reportable segments: Laboratory Solutions and Bioscience Production. Laboratory Solutions serves a broad customer base spanning research laboratories, academic institutions, healthcare settings and selected industrial applications. The segment provides a wide range of consumables, chemicals, specialty materials, workflow solutions and services used in day-to-day scientific operations. Bioscience Production focuses on the products and services needed in biopharma manufacturing, including high-purity materials, process consumables and solutions used in biologics, cell and gene therapy, and other regulated production environments. Together, these segments position Avantor both at the discovery end of science and at the production end where scale, quality and reliability are critical.
Read moreShow less
Competitively, Avantor stands out for the breadth of its portfolio, its global distribution footprint and its ability to supply mission-critical items that customers need continuously. The company reports activity across more than 180 countries and serves a very large installed customer base. This scale is strategically important because recurring, high-friction laboratory and production inputs can create sticky customer relationships, especially when quality, traceability and regulatory compliance are central to the buying decision.
Avantor’s key offerings include laboratory consumables, reagents, chemicals, high-purity materials, bioprocessing supplies, and a growing set of value-added services. The company has also emphasized centralized service centers and localized quality-control capabilities, which can help customers reduce operational complexity and free up laboratory space and staff for higher-value work. In that sense, Avantor competes not only on products but on workflow efficiency and service integration.
Recent corporate developments point to an active operational and innovation agenda. In 2025 and 2026, Avantor announced initiatives around digital traceability for smart consumables, CAR-T manufacturing support, next-generation sterile sampling solutions, and expanded microbial and stability testing capacity in the United States. Its latest quarterly commentary in 2026 highlighted stable top-line performance, with management focusing on execution, productivity and operational improvement. Overall, Avantor remains a globally diversified life-science tools platform listed on the NYSE in the United States, with exposure to structurally attractive end markets but some sensitivity to customer spending cycles and execution discipline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
